Repare Therapeutics (NASDAQ:RPTX) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• Repare Therapeutics has received a "Sell (D-)" rating from Weiss Ratings, while Wall Street Zen upgraded the stock from "Sell" to "Hold" recently, indicating mixed analyst sentiments.
• The company reported a quarterly earnings loss of ($0.39) per share, surpassing analyst estimates but with revenues significantly lower than anticipated at $0.25 million.
• Currently, Repare has a consensus rating of "Hold" with a price target of $4.50, and a substantial percentage, about 85.09%, of its shares are held by institutional investors.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by stock analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen raised Repare Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Repare Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $4.50.

Repare Therapeutics Stock Performance

Shares of NASDAQ RPTX opened at $1.82 on Wednesday. Repare Therapeutics has a twelve month low of $0.89 and a twelve month high of $4.07. The stock has a fifty day simple moving average of $1.67 and a 200-day simple moving average of $1.44. The stock has a market capitalization of $78.19 million, a PE ratio of -0.71 and a beta of 1.08.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.17. The firm had revenue of $0.25 million during the quarter, compared to analyst estimates of $2.50 million. On average, equities analysts predict that Repare Therapeutics will post -2.04 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC boosted its holdings in Repare Therapeutics by 65.5% in the fourth quarter. Millennium Management LLC now owns 170,959 shares of the company's stock valued at $224,000 after purchasing an additional 67,638 shares during the period. Affinity Asset Advisors LLC lifted its holdings in Repare Therapeutics by 100.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company's stock worth $197,000 after buying an additional 100,000 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Repare Therapeutics by 35.6% during the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company's stock worth $624,000 after buying an additional 168,230 shares during the last quarter. Rangeley Capital LLC purchased a new stake in Repare Therapeutics during the 2nd quarter worth about $494,000. Finally, Militia Capital Partners LP purchased a new stake in Repare Therapeutics during the 2nd quarter worth about $166,000. 85.09% of the stock is currently owned by hedge funds and other institutional investors.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.